Menu Search
Equities

Corbus Pharmaceuticals Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3371:DUS

Corbus Pharmaceuticals Holdings Inc

Actions
  • Price (EUR)6.50
  • Today's Change-0.10 / -1.52%
  • Shares traded250.00
  • 1 Year change-23.53%
  • Beta2.8600
Data delayed at least 15 minutes, as of Feb 11 2026 11:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

  • Revenue in USD (TTM)0.00
  • Net income in USD-67.51m
  • Incorporated2013
  • Employees28.00
  • Location
    Corbus Pharmaceuticals Holdings Inc500 River Ridge DriveNORWOOD 02062United StatesUSA
  • Phone+1 (617) 963-0103
  • Websitehttps://www.corbuspharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.